The CEOs of Johnson & Johnson, Merck, and Bristol Myers Squibb have agreed to voluntarily testify at a Senate hearing in February regarding high prescription drug prices in the US, negating the need for a planned subpoena. This decision came following Senator Bernie Sanders’s criticism of the executives for their initial refusal due to claimed lack of expertise.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
